The Aquilion One

Aquilion One CT Q & A

Arizona locations only

Q: How is the Aquilion® ONE different from other imaging systems?

A: The Aquilion ONE represents the new frontier in medical imaging. It is truly revolutionary because it provides a uniquely comprehensive exam that can reduce a patient’s diagnosis time from hours/days to mere minutes. This results in more rapid and successful treatment of patients, particularly those suffering from heart conditions, stroke, cancer and other serious medical conditions.

Q: How will it help our community?

A: The Aquilion ONE is one of the most advanced medical imaging devices available. For patients suffering from heart attack, stroke and other life-threatening conditions, the Aquilion ONE empowers physicians to make a diagnosis in minutes rather than hours or days. Before the Aquilion ONE, this same diagnosis could take hours or days and include costly, invasive procedures and more exposure to radiation and contrast dyes. Access to this revolutionary technology means patients in our community will have a better chance of recovery and a higher quality of life.

Q: What is “dynamic volume” CT?

A: Dynamic volume CT refers to the unique qualities of the Aquilion ONE, including its ability to image an entire organ in a single rotation, by acquiring volumetric data sets. The Aquilion ONE is the world’s first dynamic volume CT and allows physicians to see organ function, like how the organ and blood flow is moving within and around the organ. It also allows physicians to image the body in motion such as the movement of the spine, joints, vocal cords and lungs.

Q: How will the Aquilion ONE help treat patients?

A: The Aquilion ONE can save lives by empowering physicians to make more accurate diagnoses in minutes rather than hours or days. This is particularly important for patients experiencing heart conditions, stroke or other medical conditions, and allows physicians to detect and treat disease at its earliest stages. This means patients have a better chance of recovery and a higher quality of life.

For example, when treating a stroke patient, the Aquilion ONE could help a physician make an accurate, fast diagnosis before irreversible brain damage occurs. This faster stroke diagnosis and treatment could mean the difference in the patient remembering their family or not even knowing who they are.

Q: How will the Aquilion ONE be used by your facility?

A: As the most advanced medical imaging system available today, the Aquilion ONE will be used to conduct comprehensive exams on at-risk patients to detect disease at its earliest stages and improve the patient’s quality of life.

Q: There has been news coverage recently about radiation from CT scans. Is the Aquilion ONE safer for patients?

A: Yes. The Aquilion ONE is safe for patients and actually reduces the radiation exposure for patients by replacing several tests with one easy scan that produces fast, accurate results. Patients may not have to endure invasive diagnostic tests and will be exposed to less contrast and less radiation when scanned on the Aquilion ONE, verses the multiple tests they would undergo without it.

Q: This new technology is expensive. Will the high cost be passed on to patients?

A: No. We believe the Aquilion ONE can dramatically reduce the cost of healthcare because it can provide faster, more accurate diagnosis in minutes rather than hours or days. Since several tests are replaced with one exam, physicians can eliminate the need and cost associated with multiple procedures, extra time in the hospital/imaging center and additional risk to the patient.

Q: Where was the Aquilion ONE tested? Does it have FDA clearance?

A: The Aquilion ONE received FDA clearance in 2007. Toshiba America Medical Systems, Inc. developed the Aquilion ONE over the past 10 years with multiple prototypes and the system represents the greatest advancement in CT technology to date. Aquilion ONE beta systems were tested at some of the world’s leading medical centers, including Fujita Health University, the National Cancer Center in Japan and Johns Hopkins University in the United States.